QRFT0.120%
as of Jul 8
EW
GrowthEDWARDS LIFESCIENCES CORPORATION
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
Close · 3M
+0.88%
Held by 2 AI ETFs
AIEQ0.050%
as of Jul 20
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals1
Win rate100% (1/1)
Avg buy return+2.00%
QRFT · New entry · 1d
The AI ETF likely initiated a position in Edwards Lifesciences (EW) due to its strong 13.81% revenue growth and healthy 10.42% ROE, indicating a promising growth stock within the healthcare sector despite its high PER. This suggests the AI's algorithm projects continued market expansion or innovation potential. For retail investors, this serves as a reminder that AI funds prioritize data-driven growth and profitability metrics, even when valuations appear stretched. Investors should therefore research EW's specific market position and future catalysts to understand the full investment thesis.
weight 0 → 0.110% (new)·stock up 2.8% in the 30 days before
May 4·entry $83.33·now $85.00Fresh
+2.00%
since May 4